📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. (2014)

First Author: Libri V

Attributed to: Applying epigenetic modifying drugs to treat Friedreich's Ataxia funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(14)60382-2

PubMed Identifier: 24794816

Publication URI: http://europepmc.org/abstract/MED/24794816

Type: Journal Article/Review

Volume: 384

Parent Publication: Lancet (London, England)

Issue: 9942

ISSN: 0140-6736